Aisling Capital
SlowingNew York, NYBiotechnology, Healthcare, PharmaceuticalsLast fund filed June 2019
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Aisling Capital V | June 2019 | Indefinite | $144M | 25 |
| Aisling Capital IV | November 2015 | $400M | $143M | 14 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Steven Elms | Slowing | Medical devices, Biotech & pharma | 12 | 1 |
Classified sectors of Aisling Capital’s own portfolio companies, based on 12 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Aisling Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Lightstone Singapore | 2 | EarLens, PowerVision |
| Lightstone Ventures | 2 | EarLens, PowerVision |
| Orbimed Asia Partners | 2 | Loxo Oncology, Treeline Biosciences |
| Orbimed Genesis |
| Andrew Schiff | Quiet | Biotech & pharma, Enterprise software, Robotics & hardware | 7 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 2 |
| Loxo Oncology, Treeline Biosciences |
| Sofinnova Venture Partners | 2 | Aclaris Therapeutics, Ajax Health II |
| Vivo Innovation | 2 | Aclaris Therapeutics, TRIA Beauty |
| ARCH Venture Partners | 1 | Treeline Biosciences |
| Healthquest Partners | 1 | Ajax Health II |
| SV Life Sciences | 1 | TRANSENTERIX |
| Venbio Global Strategic | 1 | Elevation Oncology |
| Versant Venture Capital | 1 | Monte Rosa Therapeutics |
A shared board seat: a company where filings name a Aisling Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.